Starting Treatment for Parkinson's Disease: What the First Prescription Should Achieve

Newly diagnosed patients often worry both about delaying care and about using up treatment options too soon. Initial treatment is not a one-time choice of a lifelong regimen. It establishes a plan that addresses present symptoms, has assessable benefits, can be tolerated, and is practical to continue. In a consultation in China, the clinician should explain why treatment is appropriate now, why a particular option is being chosen, and how follow-up will determine whether it needs adjustment.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Record a few affected activities: whether handwriting interferes with work, how difficult fastening shoes has become, whether walking to meals is comfortable, or whether getting out of bed requires help. A symptom that appears minor to an observer may disrupt an important task. Conversely, a small tremor may not yet cause substantial functional difficulty. The patient's priorities and the examination should be considered together rather than choosing a prescription from tremor amplitude alone.
The instructions should identify the generic name, strength, release formulation, amount per dose, and administration times. If titration is required, specify the steps and who to contact if a problem occurs. “Increase slowly” leaves too much room for guessing. When prescriptions from several doctors are present, make clear which medicines continue and which are replaced so that the same ingredient is not taken twice unintentionally.
An initial visit can focus on confirming the diagnosis and establishing a sustainable regimen. Bring medicines for other illnesses, allergies, recent falls, and changes in perception or behavior. A companion familiar with daily function can contribute useful information. If adjustment requires observation, avoid arranging an unsupported complicated journey immediately after a major change. The appropriate stay depends on the actual response and review plan rather than a fixed number of days that suits every patient.

Quick answer

Full guide

Identify the difficulty before choosing the medicine

Record a few affected activities: whether handwriting interferes with work, how difficult fastening shoes has become, whether walking to meals is comfortable, or whether getting out of bed requires help. A symptom that appears minor to an observer may disrupt an important task. Conversely, a small tremor may not yet cause substantial functional difficulty. The patient's priorities and the examination should be considered together rather than choosing a prescription from tremor amplitude alone.

NICE recommends levodopa in early Parkinson's when motor symptoms affect quality of life. Where that impact is not yet substantial, levodopa, selected dopamine agonists, or MAO-B inhibitors can be discussed according to individual circumstances. Quality of life includes work, travel, social activity, and assistance needed from others, not just the ability to walk across a room. NICE early-treatment recommendations

Levodopa does not need to be reserved indefinitely

Levodopa provides substantial motor symptom benefit and is an important initial option. The AAN guideline recommends it as the preferential initial dopaminergic treatment for patients with early disease seeking motor treatment, while discussing alternatives and adverse effects. Suitability depends on functional needs and tolerability. Younger age does not automatically require postponement, and older age does not remove the need to assess dosing and side effects carefully. AAN early dopaminergic-treatment guideline

The idea that benefit is simply exhausted after a fixed number of years conflates disease progression with medication response. The later development of fluctuations or dyskinesia does not mean that levodopa has lost every useful effect. The 2024 long-term LEAP report compared starting low-dose treatment earlier with starting it 40 weeks later and found no group difference in progression or the prevalence of motor complications over the following five years. It does not justify uniformly accepting present disability to conserve future benefit, nor does it demonstrate that levodopa stops the disease. Five-year LEAP follow-up

Let trial evidence inform an individual decision

PD MED was a pragmatic randomized comparison of initial medication approaches. Patient-rated mobility-related quality of life showed a small persistent advantage for starting with levodopa. The trial was open label and studied the options available at that time; its results should not be expanded into a claim that one medicine is best for every symptom in every patient. It also illustrates why ordinary function and tolerability belong among the outcomes used to judge treatment. Original PD MED trial

A person whose main difficulty is fine hand control at work may prioritize reliable motor improvement. Someone particularly sensitive to adverse effects may need slower adjustment and closer contact with the team. The prescription should explain that tradeoff. Ask which symptoms are expected to improve and which may remain despite the first medicine. A partial but useful response should not automatically be interpreted as failure because it does not correct every difficulty.

Discuss alertness and behavior before starting a dopamine agonist

Dopamine agonists stimulate dopamine receptors and can be useful for selected patients. Their suitability also depends on risks such as sleepiness, hallucinations, standing-related dizziness, and impulse-control problems. New difficulty controlling shopping, gambling, eating, or sexual behavior can be treatment related rather than simply a change in personality or a family disagreement. The prescriber needs relevant previous history, and both patient and family should know how to report a change.

Longitudinal research links dopamine agonist exposure, dose, and duration with impulse-control disorders. A cohort's incidence cannot be treated as an individual's exact probability, but the association supports discussion before treatment and continuing observation afterward. If a problem develops, contact the clinician rather than abruptly discontinuing the drug. Adjustment must consider both movement and withdrawal-related effects. Longitudinal impulse-control study

Other early options also need a defined purpose

MAO-B inhibitors may be suitable in some early presentations, with the specific choice influenced by symptom needs and existing medicines. Potential interactions with antidepressants, analgesics, and other products should be reviewed by the prescriber and pharmacist. Anticholinergic medication is not a routine default for every patient with tremor, particularly when cognition, urinary function, and other adverse effects are concerns. Drug classes do not form a universal ladder from a harmless weak medicine to a dangerous strong one.

The 2026 Chinese fifth-edition guideline emphasizes individualized selection and gradual adjustment. Different levodopa combinations and release formulations have different practical uses. A familiar product may be chosen because it fits symptoms, local supply, and follow-up; a new package or fewer administrations per day does not alone establish a better first treatment. When a specific Chinese product is proposed, check its current prescribing information and actual hospital availability. Original Chinese fifth-edition guideline

Make the first prescription executable at home

The instructions should identify the generic name, strength, release formulation, amount per dose, and administration times. If titration is required, specify the steps and who to contact if a problem occurs. “Increase slowly” leaves too much room for guessing. When prescriptions from several doctors are present, make clear which medicines continue and which are replaced so that the same ingredient is not taken twice unintentionally.

Do not use a brand name alone to find a supposedly equivalent medicine in another country. Combination ingredients and formulations may differ. Meal instructions also need individual consideration; neither strict fasting for everyone nor eliminating dietary protein is a sensible universal rule. If nausea, poor nutrition, or food-related variation in benefit creates a problem, ask for an approach that accommodates both treatment and nutrition. Families helping with medicines should maintain one current administration chart while keeping older schedules dated for the medical history.

Review benefit and burden together after starting

Follow-up should ask more than whether the hand still shakes. Check whether targeted tasks are easier, whether benefit is sufficiently reliable, and whether nausea, dizziness, sleepiness, hallucinations, or behavioral change has appeared. Record timing rather than only describing side effects as severe. If improvement is limited, the clinician can check whether the dose is still at an initial stage, whether the schedule is being followed, whether the chosen symptom is likely to respond, and whether the diagnosis needs reconsideration.

Do not add leftover medicine to produce a better performance for one occasion or independently double a dose after an omission. Ask the prescribing team in advance how to handle missed doses, vomiting, or difficulty taking tablets. A sudden major change with severe stiffness, fever, or altered consciousness needs prompt medical attention and disclosure of the medication history. Communication allows adjustment to address the actual problem instead of cycling through unsupervised interruptions.

Begin movement and daily-activity work alongside medication

Rehabilitation need not wait for major disability. Physical therapy can establish a baseline for balance, walking, strength, and endurance, then choose suitable aerobic, resistance, and task-related practice. A sustainable plan matched to the person's risk is more useful than briefly pursuing an intensity that cannot be maintained. Exercise should not be presented as proof of cure, but it can form part of a practical routine for activity and function. APTA Parkinson's guideline

Occupational therapy can address dressing, household tasks, handwriting, and work. Recognizing an awkward environment or inefficient task strategy early may reduce avoidable difficulty. Ask which activities can be practiced independently, which need someone nearby, and how the plan fits into the existing day. A short rehabilitation course in China should lead to instructions suited to the home environment and resources available after returning. Occupational therapy practice guideline

Do not let neuroprotection claims displace useful symptom treatment

Patients understandably want to slow progression, but an early positive signal does not establish that a medicine stops Parkinson's disease. The 2025 phase III exenatide paper reported no benefit on its primary motor endpoint. The Lancet subsequently published an Expression of Concern in June 2026, so that result should not be presented as an uncontested final conclusion. The editorial notice also does not establish that the treatment works. Patients should not independently use diabetes medication for this purpose or abandon helpful current care. Read the original study with the 2026 Expression of Concern.

A medicine in the first prescription should still have an understandable purpose and an adverse-effect discussion even if it has been described as potentially neuroprotective. If research participation is of interest, clarify the study question, the place of standard treatment, screening requirements, and follow-up burden. Routine clinical prescribing and trial participation are different pathways, and the patient should know which one is being proposed.

Start in China with a plan for continuation elsewhere

An initial visit can focus on confirming the diagnosis and establishing a sustainable regimen. Bring medicines for other illnesses, allergies, recent falls, and changes in perception or behavior. A companion familiar with daily function can contribute useful information. If adjustment requires observation, avoid arranging an unsupported complicated journey immediately after a major change. The appropriate stay depends on the actual response and review plan rather than a fixed number of days that suits every patient.

Request separate renminbi estimates for consultation, necessary tests, medication, rehabilitation, and review, with the treatment period covered. Initial prescribing is usually the beginning of continuing care; the first pharmacy bill is not a budget for the whole disease course. Before returning home, check availability of the relevant formulation, the date a local clinician will take over, and the contact route if supply or tolerability becomes a problem. A plan that can be followed, observed, and adjusted is the practical result the first phase of treatment should provide.

Evidence checked: September 9, 2026. This article does not specify an individual starting dose; the clinical team must prescribe for the patient's circumstances.